Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioSeek, a subsidiary of Asterand, has entered into a two-year agreement with Cellzome, under which BioSeek is expected to use its BioMAP predictive human disease models to support and advance Cellzome's drug discovery and development projects in the treatment of inflammatory diseases.
Subscribe to our email newsletter
Cellzome vice president Biology Oliver Rausch said that the BioMAP platform will allow them to receive early insight into the human pharmacological and toxicological properties of theeir small molecules, enabling them to develop safer and more effective treatments for inflammation.
Asterand CEO Martyn Coombs said that BioMAP platform is suited for predicting possible human clinical responses of the small molecules Cellzome identifies with its proprietary screening and profiling technologies, Kinobeads and Episphere.